Eton Pharmaceuticals Inc
NASDAQ:ETON

Watchlist Manager
Eton Pharmaceuticals Inc Logo
Eton Pharmaceuticals Inc
NASDAQ:ETON
Watchlist
Price: 12.66 USD 1.28%
Market Cap: 327.1m USD
Have any thoughts about
Eton Pharmaceuticals Inc?
Write Note

Eton Pharmaceuticals Inc
Total Liabilities & Equity

Last Value
3-Years 3-Y CAGR
5-Years 5-Y CAGR
10-Years 10-Y CAGR
Quarterly
Annual
|

Eton Pharmaceuticals Inc
Total Liabilities & Equity Peer Comparison

Competitors Analysis
Latest Figures & CAGR of Competitors

Company Total Liabilities & Equity CAGR 3Y CAGR 5Y CAGR 10Y
Eton Pharmaceuticals Inc
NASDAQ:ETON
Total Liabilities & Equity
$35.8m
CAGR 3-Years
10%
CAGR 5-Years
22%
CAGR 10-Years
N/A
Johnson & Johnson
NYSE:JNJ
Total Liabilities & Equity
$178.3B
CAGR 3-Years
0%
CAGR 5-Years
3%
CAGR 10-Years
3%
Bristol-Myers Squibb Co
NYSE:BMY
Total Liabilities & Equity
$93.7B
CAGR 3-Years
-5%
CAGR 5-Years
10%
CAGR 10-Years
11%
Pfizer Inc
NYSE:PFE
Total Liabilities & Equity
$216.2B
CAGR 3-Years
6%
CAGR 5-Years
5%
CAGR 10-Years
2%
Merck & Co Inc
NYSE:MRK
Total Liabilities & Equity
$117.5B
CAGR 3-Years
8%
CAGR 5-Years
7%
CAGR 10-Years
1%
Eli Lilly and Co
NYSE:LLY
Total Liabilities & Equity
$75.6B
CAGR 3-Years
16%
CAGR 5-Years
15%
CAGR 10-Years
8%
No Stocks Found

Eton Pharmaceuticals Inc
Glance View

Market Cap
327.1m USD
Industry
Pharmaceuticals

Eton Pharmaceuticals, Inc. engages in the development, acquisition, and commercialization of prescription drug products. The company is headquartered in Deer Park, Illinois and currently employs 17 full-time employees. The company went IPO on 2018-11-09. Eton is primarily focused on hospital injectable and pediatric rare disease products. The Company’s Biorphen product is an alpha-1 adrenergic receptor agonist indicated for the treatment of clinically important hypotension resulting primarily from vasodilation in the setting of anesthesia. Its Alkindi Sprinkle product is a replacement therapy for pediatric adrenal insufficiency (AI), including congenital adrenal hyperplasia (CAH) in patients from birth to less than 17 years of age. Its product pipeline includes Zonisamide Oral liquid, Topiramate Oral Solution, Cysteine Injection, Dehydrated Alcohol Injection, Ephedrine Injection and Lamotrigine Oral Suspension. The firm's product candidates are primarily focused on two core areas: hospital-based products and pediatric oral liquid products.

ETON Intrinsic Value
13.52 USD
Undervaluation 6%
Intrinsic Value
Price

See Also

What is Eton Pharmaceuticals Inc's Total Liabilities & Equity?
Total Liabilities & Equity
35.8m USD

Based on the financial report for Sep 30, 2024, Eton Pharmaceuticals Inc's Total Liabilities & Equity amounts to 35.8m USD.

What is Eton Pharmaceuticals Inc's Total Liabilities & Equity growth rate?
Total Liabilities & Equity CAGR 5Y
22%

Over the last year, the Total Liabilities & Equity growth was 14%. The average annual Total Liabilities & Equity growth rates for Eton Pharmaceuticals Inc have been 10% over the past three years , 22% over the past five years .

Back to Top